How do I check medication monitoring when issuing high-risk drugs?

How do I check medication monitoring when issuing high-risk drugs?


Introduction

Alert
This check is still part of our prescribing system, however we now recommend you use our Proactive Prescribing Checks which we have developed to proactively check for monitoring and other potential issues  How do admin staff run Proactive Prescribing Checks?

Alert
When medication supply should be restricted, the system is now more proscriptive in how this should be managed  How do I restrict medication supply?

Medication Monitoring Checks 

This video explains how the medication monitoring checks protocol works when issuing high-risk drugs:


What Medication Is Covered

This is the list of medication monitoring that is checked by this protocol:

  • ACE inhibitor or ARB
  • ADHD Medication
  • Alfacalcidol
  • Allopurinol / Feboxustat
  • Amiodarone
  • Anti-hypertensive (change or initiation)
  • Antimetabolites
  • Antiproliferative Immunosuppressants
  • Antipsychotic
  • Antithyroid Drugs
  • Apomorphine
  • Azathioprine
  • Azithromycin
  • Ciclosporin
  • Cinacalcet
  • Dapsone
  • Denosumab
  • Diabetes Medication (change or initiation)
  • Digoxin
  • DOAC
  • Dronedarone
  • Gold
  • Lefluonimide
  • Lipid Regulating Agent
  • Lithium
  • Loop Diuretic (change or initiation)
  • Mercaptopurine
  • Mesalazine, Olsalazine or Balsalazide
  • Methotrexate
  • Midodrine
  • Minocycline
  • Mirabegron
  • Modafinil
  • Oral Retinoids
  • Other antineoplastic drugs
  • Penicillamine
  • Potassium Sparing Diuretics and Aldosterone Antagonists
  • Rifaximin
  • Sulfasalazine
  • Tacrolimus
  • Testosterone Replacement
  • Thyroid Medication
  • Thyroxine (change or initiation)
  • Valproate
  • Warfarin
Info
Unless otherwise indicated, the check is for regular monitoring. Medication that requires annual monitoring is only prompted for restrictions once its 16 months since relevant tests were completed. This is to allow time for monitoring to take place at annual reviews first.

Info
Once patients reach 14m since tests were taken, they will be included in high risk drug monitoring invites. If a patient reaches 16m, they should have had multiple invites and so be appropriate to consider restricting access to medication.